Bookmark

Add to MyYahoo RSS

Medivation News

News on Medivation (Ticker: MDVN) continually updated from thousands of sources around the net.

11 hrs ago | AmericanBankingNews.com

Medivation Receives Hold Rating from Canaccord Genuity

's stock had its "hold" rating reiterated by research analysts at Canaccord Genuity in a report released on Wednesday, Analyst Ratings News reports.

Comment?

Related Topix: Startups

Mon Apr 14, 2014

Sys-Con Media

Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys

The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 644.74, down 1.07%, and the same has fallen by 2.36% in the previous three months.

Comment?

Related Topix: Startups, Biotech, Medicine, Athersys, Healthcare Industry, Financial Markets, Achillion Pharmaceuticals, Pharmaceuticals

Thu Apr 03, 2014

BioSpace

Astellas Pharma US Announces European Regulatory Submission For...

The Phase 3 PREVAIL trial is a randomized, double-blind, placebo-controlled, multi-national trial that enrolled more than 1,700 patients at sites in .

Comment?

Related Topix: Startups, Prostate Cancer, Health, Healthcare Law, Law

KAUZ

Earnings Releases, Stock Price Movements, Company Milestone,...

Information contained on this page is provided by an independent third-party content provider.

Comment?

Related Topix: Real Estate, AvalonBay Communities, Startups, Transportation, Hertz Global, Hotels, Marriott International, Hertz Global Holdings, Consulting, Accenture

Mon Mar 31, 2014

Sys-Con Media

Medivation Names Rick Bierly Chief Financial Officer

Rick will serve as Medivation's principal financial and accounting officer and will report to David Hung, M.D., president and chief executive officer.

Comment?

Related Topix: Startups

Newswise

NCCN Receives $2.2 Million in Research Funding From Astellas and...

The National Comprehensive Cancer Network A Oncology Research Program has been awarded a $2.2-million grant from Astellas Pharma, Inc. and Medivation, Inc. to develop a program to scientifically evaluate and define the clinical effectiveness of enzalutamide in solid tumors, including bladder, breast, endometrial, hepatocellular, ovarian, and ... (more)

Comment?

Related Topix: Startups, Food and Drug Administration

Thu Mar 27, 2014

BioResearch Online

Astellas And Medivation Seek New Indication For Xtandi In sNDA To FDA

Astellas Pharma Inc. and Medivation Inc. announced in a press release that they submitted a Supplemental New Drug Application to the Food and Drug Administration .

Comment?

Related Topix: Startups, Food and Drug Administration, Taxotere, Docetaxel (generic), Medicine

Mon Mar 24, 2014

Customer Interaction Solutions

Astellas Announces Marketing Approval in Japan for XTANDI...

Astellas Pharma Inc. today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI capsules 40mg for the treatment of patients with castration-resistant prostate cancer in Japan.

Comment?

Related Topix: Marketing, Prostate Cancer, Health, Startups, Taxotere, Docetaxel (generic), Medicine

Fri Mar 21, 2014

The Motley Fool

Medivation, Inc: Fast Growing Drugs That May Become Blockbusters

Blockbuster status -- the gold medal term awarded to therapies racking up sales of more than $1 billion per year -- is the Holy Grail for drug developers.

Comment?

Related Topix: Startups, Prostate Cancer, Health

Tue Mar 18, 2014

Sys-Con Media

Astellas and Medivation Submit Supplemental New Drug Application for...

XTANDI is currently approved for the treatment of patients with mCRPC who have previously received docetaxel chemotherapy.

Comment?

Related Topix: Startups, Food and Drug Administration, Prostate Cancer, Health, Taxotere, Docetaxel (generic), Medicine, Marketing

•••
•••
•••
•••
•••

Seattle Jobs

•••
•••
•••
•••
•••